Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Circulation Année : 2021

Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction

Résumé

Background: Inflammation is a key factor of myocardial damage in reperfused ST-segment-elevation myocardial infarction. We hypothesized that colchicine, a potent anti-inflammatory agent, may reduce infarct size (IS) and left ventricular (LV) remodeling at the acute phase of ST-segment-elevation myocardial infarction. Methods: In this double-blind multicenter trial, we randomly assigned patients admitted for a first episode of ST-segment-elevation myocardial infarction referred for primary percutaneous coronary intervention to receive oral colchicine (2-mg loading dose followed by 0.5 mg twice a day) or matching placebo from admission to day 5. The primary efficacy outcome was IS determined by cardiac magnetic resonance imaging at 5 days. The relative LV end-diastolic volume change at 3 months and IS at 3 months assessed by cardiac magnetic resonance imaging were among the secondary outcomes. Results: We enrolled 192 patients, 101 in the colchicine group and 91 in the control group. At 5 days, the gadolinium enhancement-defined IS did not differ between the colchicine and placebo groups with a mean of 26 interquartile range (IQR) [16-44] versus 28.4 IQR [14-40] g of LV mass, respectively (P=0.87). At 3 months follow-up, there was no significant difference in LV remodeling between the colchicine and placebo groups with a +2.4% (IQR, -8.3% to 11.1%) versus -1.1% (IQR, -8.0% to 9.9%) change in LV end-diastolic volume (P=0.49). Infarct size at 3 months was also not significantly different between the colchicine and placebo groups (17 IQR [10-28] versus 18 IQR [10-27] g of LV mass, respectively; P=0.92). The incidence of gastrointestinal adverse events during the treatment period was greater with colchicine than with placebo (34% versus 11%, respectively; P=0.0002). Conclusions: In this randomized, placebo-controlled trial, oral administration of high-dose colchicine at the time of reperfusion and for 5 days did not reduce IS assessed by cardiac magnetic resonance imaging. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03156816.
Fichier principal
Vignette du fichier
2021 Mewton et al., Effect of.pdf (39.21 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03327902 , version 1 (29-08-2021)

Identifiants

Citer

Nathan Mewton, François Roubille, Didier Bresson, Cyril Prieur, Claire Bouleti, et al.. Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation, 2021, 144 (11), pp.859-869. ⟨10.1161/CIRCULATIONAHA.121.056177⟩. ⟨hal-03327902⟩
93 Consultations
10 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More